Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evusheld (AZD7442) for Post-Exposure Prophylaxis of COVID-19
NCT04625972Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Dec 2020; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04625972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625972.